Author

Nai-Yun Sun

National Cancer InstituteORCID 0000-0002-5401-4104Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Amber K. WeineriD· 1 shared Anjali DhalliD· 1 shared Arnulfo MendozaiD· 1 shared Brigitte C. WidemanniD· 1 shared Cristina F. ContrerasiD· 1 shared Daiki TaniyamaiD· 1 shared Dan Martinez· 1 shared Diana Grace VargheseiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Amber K. WeinerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 20, 2026

Estradiol Modulates Cytotoxic Responses to Topoisomerase II Targeting Agents in Estrogen Receptor Positive Breast Cancer Cells

Nisha Thomas, Nai-Yun Sun, Mathew Cherian

This study shows estradiol enhances the cytotoxicity of topoisomerase II poisons in ER+ breast cancer cells, suggesting E2-induced cell death relies on TOP2-mediated DNA breaks.

DOI 10.64898/2026.10.19.760233

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyNature CommunicationsPeer-reviewedJul 1, 2025

Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma

Nai-Yun Sun, Suresh Kumar, Yoo Sun Kim…·Nitin Roper

This paper identifies DLK1 as a novel immunotherapeutic target in adrenocortical carcinoma, showing it regulates tumor cell plasticity and chemoresistance, and demonstrates the efficacy of a DLK1-targeting antibody-drug conjugate.

13 citationstop 1%

humanbulk RNA-seq

𝕏 PostBluesky